European Association for the Study of Diabetes

Virta Health Reveals Triple-Digit Growth With Health Plans Amid Industry Shift Towards Diabetes Reversal

Retrieved on: 
화요일, 12월 14, 2021
Diabetes, Health, Professional Services, Insurance, Managed Care, Providence Health & Services, FDA, European Association for the Study of Diabetes, Conditional sentence, HIV disease progression rates, Physician, Population, Growth, High society, Milliman, Diabetes UK, Insulin, Humana, Lists of diseases, Risk, CEO, Association, Endocrine Society, Patient, American Diabetes Association, Disease, Multimedia, Twitter, Technology, Health, Health insurance, Pharmaceutical industry, Diabetes

Today Virta Health, the leader in type 2 diabetes reversal, announced it now works with more than 20 national and regional health plans, marking 133% year-over-year growth with large insurer customers.

Key Points: 
  • Today Virta Health, the leader in type 2 diabetes reversal, announced it now works with more than 20 national and regional health plans, marking 133% year-over-year growth with large insurer customers.
  • View the full release here: https://www.businesswire.com/news/home/20211214005989/en/
    Heightened demand for Virta coincides with an industry-wide shift towards reversal as an antidote to Americas worsening metabolic disease epidemic .
  • The tide is turning towards disease reversal as the primary goal for type 2 diabetes treatment, said Sami Inkinen, CEO and co-founder of Virta.
  • Our accelerating health plan growth affirms this shift, as payers race to cut costs while helping patients transform their health.

Senseonics Holdings, Inc. Reports Third Quarter 2021 Financial Results

Retrieved on: 
화요일, 11월 9, 2021
Diabetes, Health, Medical Devices, Safety, European Association for the Study of Diabetes, CGM, PMA, Eastern Time Zone, European Union, Doctor of Philosophy, Union, Investment, Telephone, COVID-19, Research, SENS, Diabetes Technology Society, Association, Conference, HCPS, NYSE, Review, Diabetes, Marketing, Patient, Risk, FDA, Total, Pharmaceutical industry

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended September 30, 2021.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended September 30, 2021.
  • Total revenue for the third quarter was $3.5 million compared to $0.8 million for the third quarter of 2020.
  • Third quarter 2021 sales and marketing expenses decreased by $0.7 million year-over-year, to $2.5 million.
  • Conference Call and Webcast Information:
    Company management will host a conference call at 4:30 pm (Eastern Time) today, November 9, 2021, to discuss these financial results and recent business developments.

Insulet’s Omnipod® 5 Pivotal Study Extension Data Shows Significant Improvements in Glycemic Control With One Year of Use

Retrieved on: 
목요일, 9월 30, 2021
Technology, Medical Devices, General Health, Science, Clinical Trials, FDA, Diabetes, Biotechnology, Health, Other Science, Research, Other Technology, Software, Other Health, Hardware, Data Management, Consumer Electronics, European Association for the Study of Diabetes, NASDAQ, Medical director, Patient, Association, Glucose meter, EASD, Corporation, Company, Ageing, Technology, Automated insulin delivery systems, DASH, TIR, Doctor of Philosophy, CGM, Pharmaceutical industry, Birth control

The data was presented at EASD 2021, the annual meeting of the European Association for the Study of Diabetes.

Key Points: 
  • The data was presented at EASD 2021, the annual meeting of the European Association for the Study of Diabetes.
  • Following completion of the 3-month pivotal trial, the results of which were previously shared, 95% of study participants chose to continue use of Omnipod 5 in an ongoing extension study.
  • The results were presented in 3-month intervals: months 1-3 (the pivotal study), months 4-6, months 7-9, and months 10-12.
  • Omnipod, Omnipod 5, and DASH are registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions.

Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study

Retrieved on: 
목요일, 9월 30, 2021
Heart failure, LLY, Type 2 diabetes, MRI, Eli Lilly, European Association for the Study of Diabetes, ASAT, Private Securities Litigation Reform Act, Doctor of Philosophy, Heart failure with preserved ejection fraction, Patient, Multimedia, Centers for Disease Control and Prevention, Adipose tissue, Annual general meeting, Association, Population, Glucose, U.S. Securities and Exchange Commission, VAT, Metformin, EASD, Form 10-K, United States Department of Health and Human Services, Form, NASH, Twitter, Magnetic resonance imaging, Eli Lilly and Company, Human, Company, Liver disease, Human services, Institute, Incretin, Disease, GIP, Risk, GA, Center, Facebook, View, Research, Insulin, CNR, Safety, Fatty liver disease, NYSE, Conditional sentence, Pharmaceutical industry, Medical imaging, Fine chemical

"We are encouraged by the robust reductions in liver fat content and abdominal adipose tissue observed with all three doses of tirzepatide in this population of adults with type 2 diabetes and elevated liver fat content."

Key Points: 
  • "We are encouraged by the robust reductions in liver fat content and abdominal adipose tissue observed with all three doses of tirzepatide in this population of adults with type 2 diabetes and elevated liver fat content."
  • The subpopulation of adults with type 2 diabetes who participated in this sub-study had an overall baseline LFC of 15.7 percent.
  • Greater relative reduction from baseline in LFC (29.78%-47.11% across the three doses) compared to 11.17% for insulin degludec.
  • 1Cusi, K. The effects of tirzepatide on liver fat content and abdominal adipose tissue in patients with type 2 diabetes (SURPASS-3 MRI).

Glyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy

Retrieved on: 
화요일, 9월 28, 2021
Medical Devices, Health, Diabetes, Clinical Trials, Pharmaceutical, Biotechnology, European Association for the Study of Diabetes, EASD, ZDF, Obesity, T2D, Association, GI, Type 2 diabetes, Bariatric surgery, American Diabetes Association, Pharmaceutical industry, Glyscend, Inc., Glyscend’s Polymer-based Therapy, GLYSCEND, INC., GLYSCEND’S POLYMER-BASED THERAPY

Data from earlier results were presented previously this year at the American Diabetes Association 80th Scientific Sessions.

Key Points: 
  • Data from earlier results were presented previously this year at the American Diabetes Association 80th Scientific Sessions.
  • The preclinical study results presented at EASD 2021 evaluated the metabolic effects of once-daily oral therapy in an obese T2D Zucker Diabetic Fatty (ZDF) rat model over 8 weeks.
  • Glyscend aims to replicate the beneficial effects of bariatric surgery via the duodenal exclusion mechanism, without the need for surgery.
  • Polymer-based therapies are a proven unique class of therapeutics with more than three decades of clinical experience in a wide range of applications.

WaveForm Diabetes to Present at the 57th European Association for the Study of Diabetes Meeting

Retrieved on: 
화요일, 9월 28, 2021
Cascade, Thigh, European Association for the Study of Diabetes, Bayer, Abdomen, Association, Waveform, Diabetes, Q&A, LLC, Technology, Arm, CGM, Fortune 500, Research, Loss, Forward-looking statement, Investment, Doctor of Philosophy, CE marking, EASD, Medical device, Pharmaceutical industry, Bookkeeping, Public relations

SALEM, N.H., Sept. 28, 2021 /PRNewswire/ --AgaMatrix Holdings LLC d/b/a WaveForm Diabetes, a leader in innovative solutions for glucose monitoring, today announces their selection for an oral presentation at the annual European Association for the Study of Diabetes (EASD) meeting.

Key Points: 
  • SALEM, N.H., Sept. 28, 2021 /PRNewswire/ --AgaMatrix Holdings LLC d/b/a WaveForm Diabetes, a leader in innovative solutions for glucose monitoring, today announces their selection for an oral presentation at the annual European Association for the Study of Diabetes (EASD) meeting.
  • Mihailo Rebec, PhD, Chief Technology Officer at WaveForm Diabetes, is the lead author of the study which investigates the efficacy of the WaveForm Cascade CGM system when applied to locations on the arm and thigh, versus the abdomen.
  • WaveForm most recently received CE Mark approval for 15 days of wear for their Cascade CGM system in June 2021.
  • About WaveForm Diabetes (AgaMatrix Holdings, LLC d/b/a WaveForm Diabetes)
    WaveForm Diabetes is a medical device company that develops, manufactures, and markets innovative glucose monitoring technology and related software solutions.

International Survey of Healthcare Professionals Show Preference for Blood Glucose Meters that Support People with Diabetes to Achieve Self-Management Goals

Retrieved on: 
목요일, 8월 20, 2020
Organ systems, Endocrine diseases, Endocrine pancreas, European Association for the Study of Diabetes, Diabetes, Type 2 diabetes, American Diabetes Association, Hyperglycemia, Prediabetes, Jothydev Kesavadev, Organ systems, Endocrine diseases, Endocrine pancreas, European Association for the Study of Diabetes, Diabetes, Type 2 diabetes, American Diabetes Association, Hyperglycemia, Prediabetes, Jothydev Kesavadev

Specifically, there were 151 endocrinologists, 102 primary care physicians (PCP) and 100 diabetes nurses/educators.

Key Points: 
  • Specifically, there were 151 endocrinologists, 102 primary care physicians (PCP) and 100 diabetes nurses/educators.
  • These HCPs were given the opportunity to review how blood glucose meters present information to patients on device screens from four manufacturers using interactive webpages against 8 key guideline statements.
  • The review criteria were developed using guidelines from the American Diabetes Association and the European Association for the Study of Diabetes.
  • American Diabetes Association (ADA) Standards of Medical Care in Diabetes, 2019, Management of Hyperglycemia in Type 2 Diabetes: European Association for the Study of Diabetes (EASD) & ADA, 2018).

International Survey of Healthcare Professionals Show Preference for Blood Glucose Meters that Support People with Diabetes to Achieve Self-Management Goals

Retrieved on: 
목요일, 8월 20, 2020
Organ systems, Endocrine diseases, Endocrine pancreas, European Association for the Study of Diabetes, Diabetes, Type 2 diabetes, American Diabetes Association, Hyperglycemia, Prediabetes, Jothydev Kesavadev

Specifically, there were 151 endocrinologists, 102 primary care physicians (PCP) and 100 diabetes nurses/educators.

Key Points: 
  • Specifically, there were 151 endocrinologists, 102 primary care physicians (PCP) and 100 diabetes nurses/educators.
  • These HCPs were given the opportunity to review how blood glucose meters present information to patients on device screens from four manufacturers using interactive webpages against 8 key guideline statements.
  • The review criteria were developed using guidelines from the American Diabetes Association and the European Association for the Study of Diabetes.
  • American Diabetes Association (ADA) Standards of Medical Care in Diabetes, 2019, Management of Hyperglycemia in Type 2 Diabetes: European Association for the Study of Diabetes (EASD) & ADA, 2018).

VALBIOTIS Presents Positive Results From a Study on TOTUM-63, Active Substance of VALEDIA®, Conducted by the CarMeN Laboratory in Lyon, at the Annual Meeting of the European Association for the Study of Diabetes (EASD)

Retrieved on: 
월요일, 9월 16, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Metabolism, European Association for the Study of Diabetes, Carbohydrate metabolism

This preclinical study evaluated the effect of TOTUM-63 on the secretion of certain hormones which play a fundamental role in glucose metabolism.

Key Points: 
  • This preclinical study evaluated the effect of TOTUM-63 on the secretion of certain hormones which play a fundamental role in glucose metabolism.
  • Batrice MORIO-LIONDORE*, Research Director at the CarMeN Research Laboratory, comments: "We are delighted to be presenting this study at the 55th EASD Annual Meeting.
  • The results obtained demonstrate the significant effects of TOTUM-63 on weight and glucose metabolism in this preclinical model.
  • In addition, our study aimed to evaluate the effect of TOTUM-63 on the hormonal imbalances associated with metabolic diseases.

Mundipharma Announces Launch of INVOKANA® and VOKANAMET® in Norway for the Treatment of Type 2 Diabetes as Part of Exclusive Distribution Agreement with Janssen

Retrieved on: 
수요일, 3월 20, 2019
Health, Pharmaceutical, Diabetes, Diabetes, RTT, Organ systems, Endocrine diseases, Endocrine pancreas, Canagliflozin, SGLT2 inhibitor, Metformin, Diabetes mellitus, European Association for the Study of Diabetes

The Mundipharma network of independent associated companies is pleased to launch the type-2 diabetes mellitus (T2DM) treatments Invokana (canagliflozin) and Vokanamet (canagliflozin, metformin) in Norway.

Key Points: 
  • The Mundipharma network of independent associated companies is pleased to launch the type-2 diabetes mellitus (T2DM) treatments Invokana (canagliflozin) and Vokanamet (canagliflozin, metformin) in Norway.
  • With the launch in Norway, Invokana and Vokanamet are now available across the whole of Scandinavia, following the launches in Sweden and Denmark.
  • Type 2 diabetes is a growing epidemic in Europe and effective treatments are needed to help reduce the burden of the disease in patients.
  • A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).